Ensayos clínicos

Ensayos Clínicos

Anemia Falciforme
A Phase III, Multicenter, Randomized, Double-Blind Study To Assess Efficacy And Safety Of Two Doses Of Crizanlizumab Versus Placebo, With Or Without Hydroxyurea/Hydroxycarbamide Therapy, In Adolescent And Adult Sickle Cell Disease Patients With Vaso-Occlusive Crises (STAND) (>12a).

Centros: Hospital Universitari Vall d’Hebron (Barcelona) – Dr. David Beneitez, Hospital Universitario La Paz (Madrid) – Dra. Marta Morado.

A Phase II, multicenter, randomized, open label two arm study comparing the effect of crizanlizumab + standard of care to standard of care alone on renal function in sickle cell disease patients ≥ 16 years with chronic kidney disease due to sickle cell nephropathy (STEADFAST).

Centros: Hospital Universitario Gregorio Marañón (Madrid) – Dra. Gloria Pérez Rus, Hospital Universitari Vall d’Hebron (Barcelona) – Dr. David Beneitez.

PRAISE: An adaptive, randomized, placebo controlled, double-blind, multicenter study of oral FT-4202, a Pyruvate Kinase activator in patients with sickle cell disease

Centros: Hospital Universitario La Paz (Madrid) – Dra. Marta Morado, Hospital Universitari Vall d’Hebron (Barcelona) – Dr. David Beneitez.

AG946-C-001 A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Subjects with Sickle Cell Disease.

Centro: Hospital Clínico Universitario Virgen de la Arrixaca (Murcia) – Dr. Eduardo José Salido Fiérrez.

BO42452/ A Phase Ib Randomized, Placebo-Controlled Study Evaluating The Safety, Pharmacokinetics, Pharmacodynamics, And Efficacy Of Crovalimab For The Management Of Acute Uncomplicated Vaso-Cclusive Episodes (VOE) In Patients With Sickle Cell Disease (SCD)

Centro: Hospital Universitari Vall d´Hebron (Barcelona) – Dr. David Beneitez.

BO42451/ A Randomized Double-Blind Phase 2a Study Evaluating The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Crovalimab As Adjunct Treatment In Prevention Of Acute Vaso-Occlusive Episodes (VOE) In Sickle Cell Disease (SCD)

Centro: Hospital Universitari Vall d’Hebron (Barcelona) – Dr. David Beneitez.

Anemia Hemolítica por déficit de Piruvato-Kinasa
Talasemia
Anemia Hemolítica Autoinmune
Hemoglobinuria Paroxística Nocturna
Síndrome Mielodisplásico bajo riesgo
Anémia Aplásica Adquirida
Anémia de Fanconi
PTT Congénita
© 2022 Todos los derechos reservados - Grupo Español de Eritropatología - Calle Aravaca, 12, 1ºB - 28040 Madrid

Buscar